AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01882010 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Controls
Description: Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
Study NCT03804567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oldpain2go®
Description: This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.
Study NCT03804567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine low back pain management
Description: Standard low back persistent physiotherapy management as recommended by national guidelines.
Study NCT03760159 — intervention group
Intervention type: DEVICE
Intervention: Kinocardiography unintrusive recording
Description: The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording.
Study NCT01620515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207 2.5 mg
Description: A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
Study NCT01620515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207 15 mg
Description: A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
Study NCT01129089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement
Description: Lipid-based nutrient supplement for pregnant and lactating women
Study NCT01129089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement
Description: Lipid-based nutrient supplement for infant and young children
Study NCT01129089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient powder
Description: Micronutrient powder for infant and young children
Study NCT01628718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy, cognitive version only (CPT-C)
Description: Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery.
Study NCT01511549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study NCT04481750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186-matching placebo
Description: Solution or suspension
Study NCT01511549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study NCT00536640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg per os, given daily until tumor progression
Study NCT00536640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
Study NCT00536640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
Study NCT00536640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
Study NCT00742365 — intervention group
Intervention type: DEVICE
Intervention: Bright light
Description: One hour of exposure to bright light daily upon awakening for 6 weeks.
Study NCT00742365 — intervention group
Intervention type: DEVICE
Intervention: Red light placebo
Description: One hour of exposure to red light.
Study NCT04962841 — intervention group
Intervention type: OTHER
Intervention: Nutraceuticals
Description: To observe the effect on cognitive and physical impairment.
Study NCT03525184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional protein and multi-nutrient beverage
Description: During SR+, participants will consume a multi-nutrient beverage and additional protein (\~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of \~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C \& D, zinc and omega-3 fatty acids (DHA and EPA).
Study NCT03525184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
Study NCT04079062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONO-4685
Description: Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
Study NCT04079062 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by intravenous continuous infusion at the designated speed.
Study NCT04079062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH
Description: KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
Study NCT04079062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH, ONO-4685
Description: Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
Study NCT04079062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH, placebo
Description: Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
Study NCT02502669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride 23.5 mg tablets
Study NCT02502669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride 33.5 mg tablets
Study NCT02502669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Study NCT02502669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study NCT03891004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular Skin Closure
Description: We will only close the subcuticular layer with suture
Study NCT03891004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Adhesives
Description: No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
Study NCT02027467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: StemAlive®
Study NCT02027467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (For StemAlive®)
Study NCT01418131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal tacrolimus
Description: Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
Study NCT01418131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03162484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
Study NCT03645694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Social Support Aid
Description: Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
Study NCT03913832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sirolimus drug coated balloon (SCB)
Description: Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions.
Study NCT03913832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel releasing coronary balloon catheter
Description: SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
Study NCT00384995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% (154 mEq/L) IV Sodium Chloride
Description: Saline solution
Study NCT00384995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1/6 M (166 mEq/L) IV Sodium Bicarbonate
Description: Bicarbonate solution
Study NCT00129454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session).
Study NCT02992951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DACC-Coated Post Operative Dressing
Description: Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
Study NCT00129454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session).
Study NCT00129454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
Study NCT00129454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
Study NCT03520231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: RANK Ligand Inhibitor
Study NCT03520231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab Placebo
Description: Placebo
Study NCT03520231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Antineoplastic Agent
Study NCT03520231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Antineoplastic Agent
Study NCT03520231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Antineoplastic Agent
Study NCT03520231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Antineoplastic Agent
Study NCT03520231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Antineoplastic Agent
Study NCT01546441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interprofessional assessment
Description: assessment by interprofessional team
Study NCT01546441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care in primary care clinic
Study NCT03520231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Antineoplastic Agent
Study NCT03520231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: Calcium Supplement
Study NCT03520231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Calcium Supplement
Study NCT03520231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D Supplement
Study NCT02912247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: adalimumab, 40mg,subcutaneous injection,once
Study NCT04317430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide
Description: Niclosamide tablets 1 gram once daily
Study NCT03381482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSF drawing during spinal anaesthesia
Description: 4mL of CSF by lumbar puncture
Study NCT03381482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting blood sample
Description: 6x5 mL of fasting blood sample
Study NCT03381482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar puncture
Description: 10 mL of CSF by lumbar puncture
Study NCT03255213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lingual Muscle Training
Description: Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
Study NCT04201366 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00043108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00043108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00043108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00043108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03600766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks.
Study NCT03600766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
Study NCT02509039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: 5 continuous days out of 7 days per week intermittent dosing
Study NCT02089464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBS-guided rTMS
Study NCT02089464 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Study NCT02089464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Task oriented rehabilitation
Study NCT02089464 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Task oriented rehabilitation
Study NCT03103204 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: One-stage full-mouth disinfection with chlorhexidine
Description: Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants.
Study NCT03943550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049665
Description: Multiple ascending doses of RO7049665 will be administered SC.
Study NCT03943550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered SC.
Study NCT03180437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IRE surgery
Description: IRE surgery will be used in local tumor
Study NCT03180437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRE plus γδ T cells
Description: Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
Study NCT03520231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D Supplement
Study NCT01681732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Care Plan
Description: We will develop a personalized plan based on info collected in the primary visit
Study NCT01681732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Standard Care
Description: This is the standard care arm
Study NCT02614430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vocational training
Description: The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
Study NCT02295150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Description: Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
Study NCT03752190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin
Description: intramuscular and intravenous administration
Study NCT04085510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammogram
Description: Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
Study NCT01798173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum, plasma and DNA samples
Study NCT01798173 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Serum, plasma and DNA samples
Study NCT01798173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiological exploration by CT scan or MRI
Study NCT01798173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiological exploration by CT scan or MRI
Study NCT03904953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Training
Description: Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.